The Future of Peptide‐based Drugs
- 17 December 2012
- journal article
- review article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 81 (1), 136-147
- https://doi.org/10.1111/cbdd.12055
Abstract
The suite of currently used drugs can be divided into two categories – traditional ‘small molecule’ drugs with typical molecular weights of 5000 Da that are not orally bioavailable and need to be delivered via injection. Due to their small size, conventional small molecule drugs may suffer from reduced target selectivity that often ultimately manifests in human side‐effects, whereas protein therapeutics tend to be exquisitely specific for their targets due to many more interactions with them, but this comes at a cost of low bioavailability, poor membrane permeability, and metabolic instability. The time has now come to reinvestigate new drug leads that fit between these two molecular weight extremes, with the goal of combining advantages of small molecules (cost, conformational restriction, membrane permeability, metabolic stability, oral bioavailability) with those of proteins (natural components, target specificity, high potency). This article uses selected examples of peptides to highlight the importance of peptide drugs, some potential new opportunities for their exploitation, and some difficult challenges ahead in this field.Keywords
This publication has 77 references indexed in Scilit:
- Cellular uptake of cyclotide MCoTI-I follows multiple endocytic pathwaysJournal of Controlled Release, 2011
- On-resin N-methylation of cyclic peptides for discovery of orally bioavailable scaffoldsNature Chemical Biology, 2011
- Assessing Helical Protein Interfaces for Inhibitor DesignJournal of the American Chemical Society, 2011
- Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloadditionBioorganic & Medicinal Chemistry Letters, 2011
- Chemical Re-engineering of Chlorotoxin Improves Bioconjugation Properties for Tumor Imaging and Targeted TherapyJournal of Medicinal Chemistry, 2011
- Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potencyProceedings of the National Academy of Sciences of the United States of America, 2010
- A Dual-Labeled Knottin Peptide for PET and Near-Infrared Fluorescence Imaging of Integrin Expression in Living SubjectsBioconjugate Chemistry, 2010
- An Engineered Knottin Peptide Labeled with 18F for PET Imaging of Integrin ExpressionBioconjugate Chemistry, 2009
- Contemporary strategies for the stabilization of peptides in the α-helical conformationCurrent Opinion in Chemical Biology, 2008
- Exploring β-Sheet Structure and Interactions with Chemical Model SystemsAccounts of Chemical Research, 2008